Nuclear receptors PPAR\(\beta/\delta\) and PPAR\(\alpha\): Direct distinct metabolic regulatory programs in the mouse heart

Diabetes predisposes to heart failure, particularly in combination with other comorbid conditions such as hypertension and coronary artery disease. Evidence has emerged that derangements in cardiac fuel metabolism, related to insulin-resistant and diabetic states, contribute to the development of diabetic cardiac dysfunction. The metabolic derangements in the diabetic heart involve gene regulatory programming via chronic activation of the nuclear receptor, peroxisome proliferator activated receptor \(\alpha\) (PPAR\(\alpha\)). Chronic activation of the PPAR\(\alpha\) pathway drives excessive fatty acid oxidation, lipid accumulation, reduced glucose utilization, and cardiomyopathy. PPAR\(\alpha\) is a member of a fatty-acid-activated nuclear receptor family that includes PPAR\(\gamma\) and PPAR\(\beta/\delta\). In contrast to PPAR\(\gamma\), which is expressed at low levels, PPAR\(\beta/\delta\) is highly expressed in cardiac myocytes, similar to PPAR\(\alpha\). The function of PPAR\(\alpha\) has been the subject of intense investigation; however, less is known about PPAR\(\beta/\delta\). To investigate the role of PPAR\(\beta/\delta\) in the regulation of heart metabolism and function, the authors generated transgenic mice with cardiac-specific expression of PPAR\(\beta/\delta\) driven by the myosin heavy chain (MHC-PPAR\(\beta/\delta\) mice).

Commentary

The normal adult heart satisfies its energy requirements through the oxidation of both fatty acids and glucose. However, myocardial insulin resistance and increased rates of systemic lipolysis force the diabetic heart to rely almost exclusively on fatty acid as a fuel source – a loss of substrate flexibility. Over the long term, high rates of myocardial fatty acid utilization predispose to the development of a “lipotoxic” form of cardiomyopathy, characterized by accumulation of lipid in the myocytes, mitochondrial dysfunction, and generation of reactive oxygen species related to excessive substrate flux. In addition, the diabetic heart has a reduced capacity for glycolysis and glucose oxidation, which predisposes to postischemic damage. Recent evidence has implicated dysregulation of the nuclear receptor PPAR\(\alpha\) in the metabolic and functional derangements of the diabetic heart. PPAR\(\alpha\) activates transcription of genes involved in cellular pathways of lipid utilization, including fatty acid uptake and oxidation. The PPAR\(\alpha\) gene regulatory pathway is chronically activated in the hearts of insulin-deficient and insulin-resistant rodents. Transgenic mice with cardiac-specific overexpression of PPAR\(\alpha\) (MHC-PPAR\(\alpha\) mice) display a functional and metabolic phenotype that mimics the diabetic heart; specifically, MHC-PPAR\(\alpha\) mouse hearts exhibit increased rates of fatty acid oxidation, decreased glucose utilization, myocyte accumulation of triglyceride, and cardiomyopathy. Interestingly, the lipotoxic cardiomyopathy of MHC-PPAR\(\alpha\) mice is worsened with consumption of a high-fat diet. Consistent with observations in animal models, recent studies using positron emission tomography have shown that hearts of diabetic humans exhibit increased fatty acid uptake and utilization rates.

In the study by Burkart and colleagues, the authors describe the surprising finding that, in contrast to MHC-PPAR\(\alpha\) mice, MHC-PPAR\(\beta/\delta\) mice did not develop myocyte accumulation of lipid or cardiomyopathy, even in the context of a high-fat diet. One likely explanation for this striking difference is that myocardial fatty acid uptake and esterification rates were increased in MHC-PPAR\(\alpha\) mice, but not in MHC-PPAR\(\beta/\delta\) mice. The expression of genes involved in fatty acid uptake and triglyceride synthesis was activated in the hearts of MHC-PPAR\(\alpha\) mice, but not in MHC-PPAR\(\beta/\delta\) mice. This differential gene regulation was also noted when PPAR\(\alpha\) and PPAR\(\beta/\delta\) agonists were administered to wild-type mice. Collectively, these results suggest that the striking differences in
Cardiac-resynchronization therapy in heart failure with narrow QRS complexes

Indications for cardiac resynchronization therapy (CRT) in patients with heart failure include a prolonged QRS interval (≥ 120 ms), in addition to other functional criteria. Some patients with narrow QRS complexes have echocardiographic evidence of left ventricular mechanical dyssynchrony and may also benefit from CRT. We enrolled 172 patients who had a standard indication for an implantable cardioverter-defibrillator. Patients received the CRT device and were randomly assigned to the CRT group or to a control group (no CRT) for 6 months. The primary endpoint was the proportion of patients with an increase in peak oxygen consumption of at least 1.0 mL per kilogram of body weight per minute during cardiopulmonary exercise testing at 6 months. At 6 months, the CRT group and the control group did not differ significantly in the proportion of patients with the primary endpoint (46% and 41%, respectively). In a prespecified subgroup with a QRS interval of 120 ms or more, the peak oxygen consumption increased in the CRT group (P = 0.02); it was unchanged in a subgroup with a QRS interval less than 120 ms (P = 0.45). There were 24 heart-failure events requiring intravenous therapy in 14 patients in the CRT group (16.1%) and 41 events in 19 patients in the control group (22.3%); this difference was not significant. We conclude that CRT did not improve peak oxygen consumption in patients with moderate-to-severe heart failure, providing evidence that patients with heart failure and narrow QRS intervals may not benefit from CRT. (ClinicalTrials.gov number, NCT00132977 [ClinicalTrials.gov].) Copyright 2007 Massachusetts Medical Society.

Commentary
Cardiac resynchronization therapy has been shown to improve survival and quality of life in patients with heart failure with a prolonged Q–T interval. Since the introduction of CRT, two conflicting observations have emerged: a fraction of patients presenting with large QRS complexes do not benefit from this treatment, and patients with narrow QRS complexes may present mechanical dyssynchrony. The study by Beshai and colleagues is the first prospective, controlled, double-blind randomized trial to evaluate CRT in patients with heart failure with a narrow QRS complexes and evidence of mechanical dysynchrony at echocardiography. The conclusion was that CRT did not improve peak oxygen consumption (the primary endpoint) or other secondary endpoints, including quality-of-life scores and left ventricular volumes. Possible reasons for these disappointing results may relate to the echocardiographic methods applied to detect dyssynchrony, or to lead placement, or both, but may be the consequence of a simplistic approach to the problem. Mechanical dyssynchrony—that is, a disparity in regional contraction timing—may be secondary to electrical dyssynchrony or may express regional muscle dysfunction. Dyssynchrony may be limited to systole or may extend to diastole. The more sophisticated the echocardiographic methods used, the more frequent is dyssynchrony in patients with systolic or diastolic heart failure, whether with narrow or with large QRS complexes. The clinical significance of these observations is not always obvious. However, applying CRT to all patients presenting with mechanical dyssynchrony at echocardiography, independent of knowledge of the pathogenetic mechanism, would expose to risk a growing number of non responders.

Mario Marzilli